MiMedx to acquire Sanara MedTech for $35 per share
MiMedx agreed to buy Sanara MedTech for $35 per share in cash and stock, valuing the deal at about $350 million.
Consideration is set at $33 in cash plus 0.4735 MiMedx shares per Sanara share, based on a $4.22 reference price.
MiMedx expects to fund the cash portion with cash on hand, backed by a committed $300 million term loan from Hayfin.
The deal is intended to expand MiMedx’s surgical footprint and nearly double surgical revenue; management is targeting 2027 revenue above $400 million.
Run-rate cost synergies are projected to exceed $20 million. Closing is targeted by year-end, pending Sanara shareholder approval and regulatory clearances.
SMTI•
